Switching Twice With Infliximab Biosimilars Not Linked With IBD Flare Risk
LAS VEGAS — Biosimilar switching was not tied to flare in patients with inflammatory bowel disease (IBD), according to a retrospective cohort study. Patients who switched from infliximab (Remicade) to an infliximab biosimilar, and then switched again to a different biosimilar or back to infliximab, were no more or less likely to experience a disease […]